Three-Year NHS Study Shows Blood Test Reduces Stage IV Cancer Diagnoses
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
A bipartisan House bill would require Medicaid to cover whole genome and exome sequencing for children with suspected rare diseases, aiming to improve diagnostic access and reduce costs, according to lawmakers and recent pilot programs.
The collaboration integrates AI-driven blood testing with a nationwide hepatology specialist network to reduce diagnostic delays.
The platform features enhanced speed and digital connectivity for liquid biopsy applications, with commercial release planned for mid-2026.
Read MoreUMBS-seq preserves DNA integrity while maintaining accuracy for cancer biomarker detection in liquid biopsies and tissue samples.
Read MoreThe proposed order would shift these test systems to Class II with special controls, replacing the current PMA requirement for companion diagnostics and related oncology assays.
Read MoreTwo studies show the advanced technique can identify chromosomal abnormalities missed by traditional genetic testing methods.
Read MoreStudies demonstrate artificial intelligence achieving 93% cancer diagnostic accuracy and enabling noninvasive tumor analysis through spinal fluid testing.
Read MoreThe collaboration combines SOPHiA’s DDM platform with Element’s AVITI sequencing systems to streamline genomic workflows for precision medicine research.
Read MoreResearchers identify critical flaws in Oxford Nanopore devices that could expose or alter genetic data without detection.
Read MoreThe new module enables one-step reverse transcription and amplification, removing cDNA prep and supporting applications in translational research, cell and gene therapy manufacturing, and diagnostic development.
Read MoreThe GeneSight test results led to faster initial remission and response in patients with major depressive disorder, with benefits persisting over six months.
Read MoreThe collaboration will focus on creating a cortisol biosensor for stress and metabolic health testing using luminescent biosensors and AI-guided interpretation.
Read MoreThe designation accelerates regulatory review for GeneDx’s ExomeDx and GenomeDx testing platforms designed to diagnose rare diseases.
Read MoreThe upgrade leverages technology by Ultima Genomics and processing at the Gene by Gene lab.
Read MoreThe collaboration combines Profluent’s generative AI platform with IDT’s enzyme engineering and genomics expertise to accelerate development of next-generation enzymes.
Read MoreA decade-long study shows lower rates of provider-initiated reanalysis among Hispanic, Asian, and Black patients compared with White patients.
Read MoreMulti-omics study reveals psychiatric comorbidities in bladder pain syndrome patients while demonstrating advantages in hematological malignancies and repeat expansion analysis.
Read More